Generated: May 29, 2017
|Title:||Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative|
|Abstract:||A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a thiazolidinedione derivative is herein disclosed and described.|
|Inventor(s):||Kositprapa; Unchalee (Davie, FL), Goldfarb; Robert I. (Golden Beach, FL), Cardinal; John (Tamarac, FL), Nangia; Avinash (Weston, FL)|
|Assignee:||Watson Pharmaceuticals, Inc. (Corona, CA)|
1. A once a day oral pharmaceutical tablet consisting of (a) a core; (b) a primary seal coat; (c) an immediate release pioglitazone coating; and (d) optionally an
aesthetic coating wherein: the core (a) consists of: (i) a compressed mixture of: (I) 50-98% of metformin hydrochloride; (II) 0.1-40% of a binding agent; (III) 0-20% of an absorption enhancer; and (IV) 0-5% of a lubricant; (ii) optionally a secondary
seal coat surrounding the compressed mixture; and (iii) a semipermeable membrane consisting essentially of: (I) 50-99% of a polymer selected from the group consisting of ethylcellulose, cellulose esters, cellulose diesters, cellulose triesters,
cellulose ethers, cellulose ester-ether, cellulose acylate, cellulose diacylate, cellulose triacylate, cellulose acetate, cellulose diacetate, cellulose triacetate, cellulose acetate propionate and cellulose acetate butyrate; (II) 0-40% of a flux
enhancer; and (III) 0-25% of a plasticizer, said membrane having at least one passageway formed therein for release of the metformin; the primary seal coat (b) is applied to the semipermeable membrane (iii), does not contain an active pharmaceutical
ingredient and rapidly disperses or dissolves in water; the immediate release pioglitazone coating (c) consists of: (i) 0.1-20% based upon the total weight of the tablet of pioglitazone hydrochloride; (ii) 0.1-30% based upon the total weight of the
tablet of a binder; (iii) 0-25% based upon the total weight of the tablet of a pore former; and (iv) 0-20% based upon the total weight of the tablet of a surfactant; wherein the immediate release pioglitazone coating (c) is applied to the primary seal
coat (b) that is applied to the semipermeable membrane (a)(iii) of the core (a); the tablet provides a Tmax of 8-12 hours for the metformin and a Tmax of 1-4 hours for the pioglitazone: the tablet exhibits the following metformin dissolution profile
when tested in a USP Type 2 apparatus at 75 rpms in 900 ml of simulated intestinal fluid and 37.degree. C.: 0-15% of the metformin is released after two hours; 20-40% of the metformin is released after four hours; 45-90% of metformin is released after
eight hours; and not less than 60% of the metformin is released after twelve hours; and the tablet exhibits the following pioglitazone dissolution profile when tested in a USP apparatus Type 1 apparatus at 100 rpm in a pH 2.0 HCl-0.3M KCl buffer
solution: at least 79% of the pioglitazone is released after 20 minutes and at least 95% of the pioglitazone is release after 30 minutes.
2. The tablet of claim 1 wherein the immediate release pioglitazone coating is applied to the primary seal coating using a solvent mixture of water and an organic solvent.
3. The tablet of claim 1 wherein the compressed mixture of the core consists of: (I) 75-95% of metformin hydrochloride; (II) 3-15% of a binding agent; (III) 2-10% of an absorption enhancer; and (IV) 0.5-1% of a lubricant.
4. The tablet of claim 1 wherein the polymer of the semipermeable membrane is cellulose acetate.
5. The tablet of claim 1 wherein the polymer of the semipermeable membrane is cellulose acetate.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.